Felix Gerhard Maria Dietlein, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorine Radioisotopes | 3 | 2020 | 468 | 1.330 |
Why?
|
Glutamate Carboxypeptidase II | 2 | 2020 | 78 | 0.920 |
Why?
|
Prostatic Neoplasms | 8 | 2021 | 10651 | 0.880 |
Why?
|
Gallium Radioisotopes | 5 | 2021 | 154 | 0.780 |
Why?
|
Oligopeptides | 3 | 2019 | 1275 | 0.680 |
Why?
|
Antigens, Surface | 2 | 2020 | 1851 | 0.660 |
Why?
|
Urea | 2 | 2016 | 440 | 0.640 |
Why?
|
Niacinamide | 1 | 2019 | 435 | 0.640 |
Why?
|
Nucleotides | 1 | 2020 | 442 | 0.630 |
Why?
|
DNA Repair | 4 | 2020 | 2061 | 0.630 |
Why?
|
Lysine | 3 | 2016 | 1042 | 0.570 |
Why?
|
Neoplasms | 9 | 2022 | 20568 | 0.550 |
Why?
|
DNA-Activated Protein Kinase | 1 | 2014 | 117 | 0.500 |
Why?
|
Organometallic Compounds | 1 | 2016 | 663 | 0.470 |
Why?
|
Edetic Acid | 3 | 2019 | 283 | 0.470 |
Why?
|
DNA Repair Enzymes | 1 | 2014 | 360 | 0.450 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2020 | 8943 | 0.430 |
Why?
|
Drug Synergism | 2 | 2018 | 1880 | 0.430 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2020 | 1544 | 0.430 |
Why?
|
Gallium Isotopes | 3 | 2021 | 4 | 0.420 |
Why?
|
Promoter Regions, Genetic | 2 | 2022 | 6051 | 0.410 |
Why?
|
ras Proteins | 1 | 2015 | 1117 | 0.370 |
Why?
|
Mutation | 7 | 2022 | 29491 | 0.330 |
Why?
|
Protein Kinases | 1 | 2015 | 1684 | 0.330 |
Why?
|
Kallikreins | 2 | 2020 | 267 | 0.310 |
Why?
|
Computational Biology | 1 | 2020 | 3568 | 0.310 |
Why?
|
Tissue Distribution | 3 | 2021 | 2407 | 0.310 |
Why?
|
Prostate-Specific Antigen | 4 | 2021 | 2281 | 0.300 |
Why?
|
Enzyme Inhibitors | 2 | 2015 | 3933 | 0.300 |
Why?
|
Antineoplastic Agents | 5 | 2018 | 13754 | 0.300 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 260 | 0.270 |
Why?
|
Proteins | 1 | 2020 | 6166 | 0.260 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 3010 | 0.260 |
Why?
|
Kidney | 1 | 2019 | 6910 | 0.250 |
Why?
|
Signal Transduction | 6 | 2020 | 23996 | 0.250 |
Why?
|
Ligands | 3 | 2019 | 3334 | 0.240 |
Why?
|
Radiopharmaceuticals | 3 | 2020 | 2760 | 0.230 |
Why?
|
Proto-Oncogene Proteins | 1 | 2015 | 4697 | 0.220 |
Why?
|
Colonic Neoplasms | 1 | 2014 | 2532 | 0.220 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6370 | 0.210 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2018 | 355 | 0.210 |
Why?
|
DNA Repair-Deficiency Disorders | 1 | 2020 | 28 | 0.200 |
Why?
|
Receptor, EphA2 | 1 | 2020 | 44 | 0.200 |
Why?
|
Apoptosis | 3 | 2016 | 10119 | 0.190 |
Why?
|
Nuclear Proteins | 2 | 2017 | 5988 | 0.180 |
Why?
|
Neurofibromin 1 | 1 | 2020 | 204 | 0.180 |
Why?
|
Genomics | 2 | 2021 | 5338 | 0.180 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1671 | 0.180 |
Why?
|
Lung Neoplasms | 6 | 2020 | 12607 | 0.170 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2022 | 778 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2020 | 1949 | 0.170 |
Why?
|
Gene Fusion | 1 | 2021 | 376 | 0.170 |
Why?
|
Whole Body Imaging | 1 | 2019 | 281 | 0.160 |
Why?
|
Isotope Labeling | 1 | 2019 | 431 | 0.160 |
Why?
|
GTP Phosphohydrolases | 1 | 2020 | 516 | 0.160 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 562 | 0.160 |
Why?
|
Cell Line, Tumor | 8 | 2021 | 16989 | 0.150 |
Why?
|
DNA Damage | 3 | 2016 | 2470 | 0.150 |
Why?
|
Propranolol | 1 | 2018 | 517 | 0.150 |
Why?
|
Oncogenes | 1 | 2022 | 1259 | 0.150 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9804 | 0.150 |
Why?
|
Serine | 1 | 2020 | 857 | 0.140 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 4954 | 0.140 |
Why?
|
Parkinsonian Disorders | 1 | 2018 | 265 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 571 | 0.130 |
Why?
|
Germany | 1 | 2016 | 837 | 0.130 |
Why?
|
Humans | 30 | 2022 | 717237 | 0.130 |
Why?
|
Molecular Targeted Therapy | 2 | 2017 | 2865 | 0.130 |
Why?
|
Cysteine Endopeptidases | 1 | 2016 | 662 | 0.120 |
Why?
|
Positron-Emission Tomography | 3 | 2021 | 6295 | 0.120 |
Why?
|
DNA Mutational Analysis | 1 | 2022 | 4312 | 0.120 |
Why?
|
Cluster Analysis | 1 | 2020 | 2759 | 0.110 |
Why?
|
Androgen Antagonists | 1 | 2021 | 1285 | 0.110 |
Why?
|
Cell Survival | 2 | 2021 | 6133 | 0.110 |
Why?
|
Neoplasms, Experimental | 2 | 2018 | 1332 | 0.110 |
Why?
|
Male | 14 | 2022 | 351380 | 0.110 |
Why?
|
Melanoma | 2 | 2020 | 5260 | 0.110 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1230 | 0.110 |
Why?
|
Neoplasm Transplantation | 1 | 2015 | 2149 | 0.100 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 1262 | 0.100 |
Why?
|
Recurrence | 2 | 2019 | 8282 | 0.100 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 5495 | 0.090 |
Why?
|
Thyroid Neoplasms | 1 | 2022 | 2229 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2015 | 3697 | 0.090 |
Why?
|
Gene Amplification | 1 | 2013 | 1079 | 0.090 |
Why?
|
Drug Design | 1 | 2014 | 1107 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2018 | 1923 | 0.090 |
Why?
|
Mice | 9 | 2021 | 81126 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8685 | 0.080 |
Why?
|
Angiogenesis Inhibitors | 1 | 2018 | 2081 | 0.080 |
Why?
|
Reproducibility of Results | 2 | 2016 | 19538 | 0.080 |
Why?
|
Tumor Cells, Cultured | 1 | 2015 | 6564 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3512 | 0.080 |
Why?
|
Animals | 11 | 2021 | 170890 | 0.080 |
Why?
|
Bayes Theorem | 1 | 2013 | 2045 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2972 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11200 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 4750 | 0.070 |
Why?
|
Genome | 1 | 2013 | 1755 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 1902 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2020 | 5335 | 0.060 |
Why?
|
Aged | 5 | 2020 | 162856 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 3016 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 8109 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18352 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4916 | 0.050 |
Why?
|
Zirconium | 1 | 2021 | 100 | 0.050 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14903 | 0.050 |
Why?
|
Platinum | 1 | 2022 | 221 | 0.050 |
Why?
|
Quinolines | 2 | 2018 | 739 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4472 | 0.050 |
Why?
|
Radioisotopes | 1 | 2021 | 501 | 0.050 |
Why?
|
Prevalence | 1 | 2016 | 14896 | 0.050 |
Why?
|
Carboplatin | 1 | 2022 | 807 | 0.040 |
Why?
|
Open Reading Frames | 1 | 2022 | 837 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 5101 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8013 | 0.040 |
Why?
|
Cyclin T | 1 | 2017 | 19 | 0.040 |
Why?
|
Middle Aged | 4 | 2019 | 215041 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 9 | 1 | 2017 | 71 | 0.040 |
Why?
|
Naphthalenes | 1 | 2018 | 195 | 0.040 |
Why?
|
Azoxymethane | 1 | 2016 | 34 | 0.040 |
Why?
|
Microsatellite Instability | 1 | 2020 | 672 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 39887 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2021 | 72614 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2018 | 553 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2018 | 9927 | 0.030 |
Why?
|
Intestinal Neoplasms | 1 | 2016 | 297 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1301 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1928 | 0.030 |
Why?
|
RNA Polymerase II | 1 | 2017 | 542 | 0.030 |
Why?
|
Prostate | 1 | 2021 | 1604 | 0.030 |
Why?
|
Diamines | 1 | 2012 | 58 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2018 | 718 | 0.030 |
Why?
|
Genes, myc | 1 | 2013 | 406 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1056 | 0.030 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2013 | 466 | 0.030 |
Why?
|
Organic Chemicals | 1 | 2012 | 221 | 0.030 |
Why?
|
Ubiquitination | 1 | 2016 | 1025 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2012 | 254 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2020 | 3704 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2017 | 942 | 0.030 |
Why?
|
Drug Utilization | 1 | 2018 | 1223 | 0.030 |
Why?
|
Quinazolines | 1 | 2018 | 1424 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20083 | 0.030 |
Why?
|
Piperidines | 1 | 2018 | 1602 | 0.020 |
Why?
|
Genetic Heterogeneity | 1 | 2013 | 751 | 0.020 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2016 | 866 | 0.020 |
Why?
|
Risk Factors | 1 | 2016 | 70864 | 0.020 |
Why?
|
Immunoblotting | 1 | 2012 | 1792 | 0.020 |
Why?
|
Mice, Nude | 1 | 2015 | 3830 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 3100 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2017 | 4329 | 0.020 |
Why?
|
DNA Primers | 1 | 2012 | 2999 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2018 | 2716 | 0.020 |
Why?
|
Caenorhabditis elegans | 1 | 2016 | 1423 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 5038 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2012 | 997 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17432 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 2974 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11777 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2017 | 3511 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2015 | 7056 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4935 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10542 | 0.020 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 5271 | 0.020 |
Why?
|
Female | 5 | 2022 | 377909 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7952 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2015 | 11276 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58528 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 6132 | 0.010 |
Why?
|
Gene Expression | 1 | 2013 | 8013 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10376 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 22929 | 0.010 |
Why?
|
Liver | 1 | 2015 | 7628 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 16693 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2013 | 4038 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12073 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39302 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11336 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 51275 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9532 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2013 | 62348 | 0.000 |
Why?
|